Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Xeljanz Pulmonary Embolism Problems 5-Fold Higher Than Other Rheumatoid Arthritis Drugs: Study April 16, 2019 Irvin Jackson Add Your Comments According to preliminary results from an on-going clinical trial, side effects of Xeljanz at higher doses may increase the risk of pulonary embolism problems by a factor of five when compared to other rheumatoid arthritis drug. In February, the FDA issued a drug safety communication about the potential pulmonary embolism risks from Xeljanz, which was echoed late last month by European regulators as well, recommending that doctors closely monitor patients for signs of serious and potentially life-threatening blood clot problems. Those assessments came following the recent release of results by Pfizer, which is conducting a clinical trial to assess the risk of cardiovascular problems from Xeljanz, but raised serious concerns about the off-label use of the drug at 10 mg twice daily doses. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Preliminary results of the study showed that the overall incidence of Xeljanz pulmonary embolism problems was five times higher among users taking higher doses when compared to individuals using other rheumatoid arthritis drugs that are part of a class known as TNF inhibitors, which includes blockbuster drugs like Humira, Enbrel and others. In addition, when comparing use of the 10mg twice daily dose to the 5mg twice daily dose, the results suggest that users still face a three-fold higher risk of pulmonary embolism. Xeljanz (tofacitinib) is a drug that was first approved by the FDA in 2012 to treat adults with rheumatoid arthritis, which is an autoimmune disorder that causes inflammation of the joints in approximately one percent of the population. The drug was designed to block the activity of certain enzymes in the body that affect immune system function and is commonly used as an alternative for patients who have tried methotrexate and other medications without success. In December of 2017, the FDA approved the use of Xeljanz and Xeljanz XR for the treatment of active psoriatic arthritis (PsA), and then approval was expanded again in May 2018 to include treatment of moderate to severe active ulcerative colitis, which includes the 10mg twice daily dose. As part of the drugs approval process, the FDA required a post-marketing study to evaluate the safety of the drug in separate doses to assess the risk of cardiovascular events. After evaluating data from the Xeljanz clinical trial results, the drug manufacturer Pfizer announced that patients receiving 10 mg doses of Xeljanz twice per day were found to have a significantly higher risk of experiencing pulmonary embolisms and had an overall higher rate of mortality when compared to patients taking 5 mg doses of Xeljanz. European regulators further indicated that it appears the problem is when rheumatoid arthritis patients, typically given the 5 mg daily dose, are prescribed the 10 mg dose typically given to ulcerative colitis patients. Additional concerns raised in the clinical trial found patients taking Xeljanz were at an increased risk for developing serious infections including tuberculosis, invasive fungal infections and bacterial and viral infections that resulted in hospitalizations and deaths. Pfizer announced if a patients develops an infection while using Xeljanz, treatment should be interrupted until the infection is controlled. Pfizer, in conjunction with the FDA, announced they will begin reassessing dosage levels and infection warnings raised during the clinical trial. Healthcare professionals are being encouraged to follow the updated Xeljanz prescribing information and monitor all patients for symptoms of pulmonary embolism. Patients are being asked to not change their dose of Xeljanz before consulting with their healthcare professional, as doing so could worsen their condition. Patients taking Xeljanz who begin to experience sudden shortness of breath, chest pain, difficulty breathing, coughing up blood, excessive sweating or clammy or bluish colored skin should seek immediate medical help. Tags: Pfizer, Pulmonary Embolism, Rheumatoid Arthritis, Ulcerative Colitis, Xeljanz Image Credit: | More Xeljanz Lawsuit Stories Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study November 8, 2023 Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023 Drugs Advertised on TV Often Have Low Therapeutic Value, Study Finds January 26, 2023 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: yesterday) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025) Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 2 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024) Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (Posted: 2 days ago) A federal judge will meet with lawyers involved with Suboxone tooth loss lawsuits tomorrow, to review the status of pretrial proceedings in claims brought by individuals throughout the U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITPrenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)Suboxone Lawsuit Filing Deadline Nears for Many Tooth Decay Claims in 3-Year SOL States (04/07/2025)Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (03/17/2025)
Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023
More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: yesterday) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)
Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 2 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)
Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (Posted: 2 days ago) A federal judge will meet with lawyers involved with Suboxone tooth loss lawsuits tomorrow, to review the status of pretrial proceedings in claims brought by individuals throughout the U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITPrenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)Suboxone Lawsuit Filing Deadline Nears for Many Tooth Decay Claims in 3-Year SOL States (04/07/2025)Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (03/17/2025)